↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Theramex's 4x markup in six years signals women's health platforms now trade at corporate-grade multiples, with sponsor exits increasingly targeting strategic buyers at **15x+ EBITDA**.
£2.2 billion
The price represents a four-times multiple on the asset's
2018 valuation
when the sellers acquired it
£550 million
then expanded the platform through seven bolt-on acquisitions including…
€140 million
purchase of Sérélys from Laboratoires Chauvin in 2021
Cinven closed its acquisition of Theramex, the women's health pharmaceutical platform, from Carlyle and PAI Partners for approximately £2.2 billion. The price represents a four-times multiple on the asset's 2018 valuation when the sellers acquired it, marking Theramex as the third women's health platform to change hands among top-tier sponsors in the past eighteen months.
Theramex operates across menopause treatments, fertility solutions, and contraceptive portfolios in forty-four countries. The company generates revenue through direct-to-specialist sales channels rather than broad retail distribution, a structure that produces higher margins and stickier prescriber relationships. Carlyle and PAI bought the business in 2018 from Nordic Capital for approximately £550 million, then expanded the platform through seven bolt-on acquisitions including the €140 million purchase of Sérélys from Laboratoires Chauvin in 2021. Revenue grew from roughly £180 million at entry to an estimated £320 million at exit, with EBITDA margins widening from the mid-twenties to the low thirties.
The valuation step-up reflects two parallel trends. First, women's health assets now trade at premiums to general pharmaceutical platforms because regulatory tailwinds and demographic shifts create visible demand curves. Menopause treatments alone represent a $15 billion addressable market growing at high single digits annually as the fifty-to-sixty-five age cohort expands in Western Europe and North America. Second, sponsor-to-sponsor deals for specialist platforms consistently clear at twelve-to-fifteen-times EBITDA when the business demonstrates pricing power and limited generic erosion. Theramex fits that profile cleanly.
Cinven enters with a proven healthcare roll-up model, having executed similar platform builds with behavioral health and diagnostics assets. The firm will likely add three to five acquisitions over a four-year hold period, targeting European women's health brands generating £20-80 million in revenue. The strategic question is whether Cinven pursues a secondary exit to another sponsor or positions Theramex for a corporate buyer—Pfizer, Organon, or Bayer—seeking to rebuild women's health divisions after years of divestitures. Corporate buyers have paid seventeen-to-twenty-times EBITDA for scaled platforms in this category when strategic fit is clean.
Watch for two near-term signals. First, any acquisition announcements from Cinven within six months indicate aggressive platform expansion rather than margin optimization. Second, monitor whether Organon or Bayer resurface as buyers for mid-sized women's health assets in Europe, which would validate the multiple expansion thesis and suggest Theramex could command £3+ billion at exit if revenue crosses £500 million.
Carlyle deployed roughly €200 million of equity in 2018 and exits with a 2.8x gross multiple after six years—solid but unremarkable for a healthcare platform in a growth category. The real return came from margin expansion, not revenue multiplication, which raises the question of how much organic growth remains for the next owner versus how much relies on M&A execution.
Branded by POPS4 · proof in 60 seconds
For the principal
Women's health platforms with direct specialist channels now clear at 12-15x EBITDA in sponsor-to-sponsor deals; consider exposure through secondaries or co-investments in similar assets.
For the operator
Track Cinven's first bolt-on within six months; if they add £50M+ revenue quickly, the exit thesis is corporate sale at 17x+, not financial sponsor round-trip.
For the house
Flag Theramex for coverage if Cinven pursues a sale process in year three; potential £3B+ exit to Organon or Bayer warrants tracking named-account positioning in European pharma.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.